Home > Pressrelease > Automated Cell Counter Market size to exceed $9bn by 2030

Automated Cell Counter Market size to exceed $9bn by 2030

  • Published Date: October 3, 2022

Automated Cell Counter Market is anticipated to cross USD 9 billion by 2030, according to a new research report by Global Market Insights Inc.

The study recognizes inflowing research & development investments across the globe as one of the significant factors bolstering the demand for automated cell counters. The considerable rise in global disease burden and the growing prevalence of infectious diseases such as Ebola and COVID-19 have triggered the requirement for effective preventive therapies and diagnostic solutions.

Growing emphasis on new product development to aid the adoption of flow cytometer

Automated cell counter market from flow cytometer segment accounted for more than USD 3.3 billion in 2021. Increasing utilization of flow cytometry technique for the evaluation of peripheral blood, bone marrow, and other bodily fluids as well as for detecting conditions such as anemia, leucocytosis, polycythemia, etc., may drive product sales in the coming years. Besides, the growing emphasis on the development & commercialization of advanced flow cytometer devices with simple operations, streamlined workflows, and quicker TATs may support the industry expansion.

Browse key industry insights spread across 165 pages with 183 market data tables & 15 figures & charts from the report, “Automated Cell Counter Market Size By Product Type (Fluorescence Image-based Cell Counter, Flow Cytometers, Coulter Counter), By Application (Blood Cells, Microbial Cells, Cell Lines), By End-use (Hospitals, Diagnostic Laboratories, Research Institutes, Pharmaceutical & Biotechnology Companies), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022 – 2030”, in detail along with the table of contents:

Increasing R&D in pharma to foster market trends

Automated cell counter market from microbial cell segment is speculated to expand at over 5% CAGR through 2030. The extensive utilization of microbial cell counting techniques in a broad spectrum of applications ranging from probiotic manufacturing and vaccine preparation to waste management and soil contamination may create new growth prospects for the market. Additionally, the significant rise in R&D investments across the life sciences and pharmaceutical sectors, coupled with the introduction of new biological therapies will spur the business landscape.

Growing awareness about timely disease diagnosis to boost the industry size

Others segment is likely to reach USD 1 billion by 2030. The rising awareness pertaining to early disease diagnosis has pushed demand for advanced blood tests, diagnostic procedures, and cutting-edge equipment across healthcare settings. Besides, the ongoing advancements in gene, drug, and other preventive therapies may drive demand for automated cell counters.

Rising prominence of chronic diseases will propel market forecasts in Asia Pacific

Asia Pacific automated cell counter market is expected to surpass USD 2 billion by 2030. The growing prevalence of diseases such as cancer and HIV and the subsequent technological advancements in stem cell therapy for early disease detection may fuel regional market trends. In addition, the increasing R&D investments and the expanding healthcare infrastructure may positively influence the market growth trajectory.

Regulatory approvals to stimulate the competitve landscape

Notable companies in the automated cell counter industry include Abbott Laboratories, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc,  Danaher (Beckman Coulter Inc. and Radiometer), Sysmex Corporation, NanoEnTek, F. Hoffmann-La Roche Ltd, Olympus Corporation, Agilent Technologies, Inc., PerkinElmer, Inc. These players are strengthening their technological outlook to deliver state-of-the-art products in the market in order to boost their product portfolio and generate significant revenues.

For instance, in June 2022, Sysmex Corporation obtained FDA clearance for its XN-10 hematology analyzer with blood bank mode. It is a technologically advanced automated hematology analyzer for white blood cell counting.

Authors: Sumant Ugalmugle, Rupali Swain